<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572974</url>
  </required_header>
  <id_info>
    <org_study_id>PS0056</org_study_id>
    <nct_id>NCT01572974</nct_id>
  </id_info>
  <brief_title>Quality of Life in Barrett's Esophagus and Gastro-Esophageal Reflux Disease</brief_title>
  <official_title>Quality of Life in Barrett's Esophagus and GERD:GERD Symptoms, Perception of Cancer Risk, and Actual Cancer Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Midwest Biomedical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kansas City Veteran Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Midwest Biomedical Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Compare the overall quality of life of patients with no Barrett's esophagus ,
      non-dysplastic Barrett's Esophagus (NDBE), Barrett's esophagus with low grade dysplasia
      (LGD), and Barrett's esophagus with high grade dysplasia (HGD). We also Compare the overall
      quality of life of Barrett's esophagus patients with severe gastroesophageal reflux disease
      (GERD) symptoms to those with no GERD symptoms
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The presence of GERD symptoms is associated with a significant decrease in quality of
      life.While a diagnosis of Barrett's esophagus is also associated with a decrease in quality
      of life, these studies evaluated Barrett's esophagus patients with GERD symptoms.It is
      unclear whether decrements in quality of life from cancer risk in patients with Barrett's
      esophagus are due to actual cancer risk or a patient's false perception.Here we Compare the
      overall quality of life of patients with no Barrett's esophagus , non-dysplastic Barrett's
      Esophagus (NDBE), Barrett's esophagus with low grade dysplasia (LGD), and Barrett's esophagus
      with high grade dysplasia (HGD). The Investigators will also Compare the overall quality of
      life of Barrett's esophagus patients with severe gastroesophageal reflux disease (GERD)
      symptoms to those with no GERD symptoms. Finally the investigators will compare the overall
      quality of life of patients with a perceived low risk of esophageal cancer to those with a
      perceived high risk of esophageal cancer
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of recruitment
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Health State Utility as measured by the Time Trade-off (TTO) method/Standard Gamble (SG) method</measure>
    <time_frame>1 year</time_frame>
    <description>questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SF-36 physical function (PF) subscale</measure>
    <time_frame>12 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 role limitations-physical (RP) subscale</measure>
    <time_frame>12 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 general health (GH) subscale</measure>
    <time_frame>12 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">89</enrollment>
  <condition>Barrett's Esophagus</condition>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>No Barrett's esophagus</arm_group_label>
    <description>Subject without columnar lined esophagus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nondysplastic BE</arm_group_label>
    <description>Subject with columnar lined esophagus and absence of dysplasia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low grade dysplastic BE</arm_group_label>
    <description>subject with columnar lined esophagus and presence of low grade dysplasia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High grade dysplastic BE</arm_group_label>
    <description>subject with columnar lined esophagus and presence of high grade dysplasia</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is a Veteran population presenting to a VA Hospital with GERD symptom
        or Barrett's esophagus
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 18 or above

        At least one of the following:

        Previous diagnosis of Barrett's esophagus Presence of GERD symptoms per patient report

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prateek Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kansas City VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kansas City VA Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gerson LB, Ullah N, Hastie T, Triadafilopoulos G, Goldstein M. Patient-derived health state utilities for gastroesophageal reflux disease. Am J Gastroenterol. 2005 Mar;100(3):524-33.</citation>
    <PMID>15743346</PMID>
  </reference>
  <reference>
    <citation>Crockett SD, Lippmann QK, Dellon ES, Shaheen NJ. Health-related quality of life in patients with Barrett's esophagus: a systematic review. Clin Gastroenterol Hepatol. 2009 Jun;7(6):613-23. doi: 10.1016/j.cgh.2009.02.024. Epub 2009 Mar 10. Review.</citation>
    <PMID>19281858</PMID>
  </reference>
  <reference>
    <citation>Eloubeidi MA, Provenzale D. Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol. 2000 Aug;95(8):1881-7.</citation>
    <PMID>10950030</PMID>
  </reference>
  <reference>
    <citation>Shaheen NJ, Green B, Medapalli RK, Mitchell KL, Wei JT, Schmitz SM, West LM, Brown A, Noble M, Sultan S, Provenzale D. The perception of cancer risk in patients with prevalent Barrett's esophagus enrolled in an endoscopic surveillance program. Gastroenterology. 2005 Aug;129(2):429-36.</citation>
    <PMID>16083700</PMID>
  </reference>
  <reference>
    <citation>Kruijshaar ME, Siersema PD, Janssens AC, Kerkhof M, Steyerberg EW, Essink-Bot ML; CYBAR Study Group. Patients with Barrett's esophagus perceive their risk of developing esophageal adenocarcinoma as low. Gastrointest Endosc. 2007 Jan;65(1):26-30.</citation>
    <PMID>17185076</PMID>
  </reference>
  <reference>
    <citation>Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.</citation>
    <PMID>1593914</PMID>
  </reference>
  <reference>
    <citation>Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, Lind T, Meyer-Sabellek W, Malfertheiner P, Stolte M, Willich SN. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003 Oct 15;18(8):767-76.</citation>
    <PMID>14535869</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Midwest Biomedical Research Foundation</investigator_affiliation>
    <investigator_full_name>PRATEEK SHARMA</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Barrett's esophagus</keyword>
  <keyword>Gastroesophageal reflux disease</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

